FDA approves Novartis' $2 million gene therapy for spinal muscular atrophy

The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting one in every 11,000 live births.